Alnylam Pharmaceuticals Inc at H C Wainwright Hepatitis B Virus (HBV) Mini-Conference (Virtual) Transcript
Welcome back to our afternoon session. First we're going to start with a panel discussion with Vir Biotechnology and Alnylam Pharmaceuticals. From Alnylam we have Vasant Jadhav, VP of Research and from Vir Biotechnology we have Phil Pang, Chief Medical Officer. Thank you both for joining us today.
Questions & Answers
And I think the best place to begin is to just give us a background on Alnylam's sRNA platform, as well as, tell us about the Vir and Alnylam collaboration in HBV. How far back does this go? How closely did the R&D teams work together? And then we'll have some follow-ups from there.
Sounds good, Patrick. Hey, it's a pleasure to be here. My -- again, my name is Vasant Jadhav
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
